BiotechTube
Home/Coya Therapeutics/Ann Maurer
AM

Ann Maurer

Chief Financial Officer

Coya Therapeutics

Therapeutic Areas

Neurodegenerative DiseasesAutoimmune DisordersMetabolic Diseases

Coya Therapeutics Pipeline

DrugIndicationPhase
COYA 302Amyotrophic Lateral Sclerosis (ALS)Phase 2
COYA 201Undisclosed Inflammatory IndicationsPreclinical
COYA 101Undisclosed Autoimmune IndicationsPreclinical

Leadership Team at Coya Therapeutics

DH
Dr. Howard Berman
Executive Chairman of the Board
DS
Dr. Stanley H. Appel
Co-founder and Chairman Emeritus
DA
Dr. Arun Swaminathan
Chief Executive Officer
DF
Dr. Fred Grossman
Chief Medical Officer
View full Coya Therapeutics profile